Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03923049 · ClinicalTrials.gov registry record · NA

Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis

A NA study, sponsored by University of Alabama at Birmingham.

Terminated
Registry status
NA
Development phase
5
Enrollment target

NCT03923049 is a NA study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 5 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03923049, a NA study, was terminated before completion, sponsored by University of Alabama at Birmingham.

TERMINATED
Registry status
NA
Development phase
5 participants
Enrollment target

Study Summary

The purpose and objectives of the study is to establish the feasibility of the simultaneous PET/MR in patients with cardiac sarcoidosis, determine relationships between various imaging biomarkers like extracellular volume (ECV) and standardized uptake values (SUV) from FDG-PET and to evaluate the diagnostic accuracy of the simultaneous method in comparison to the PET/CT and cardiac MRI.

Interventions

  • DIAGNOSTIC_TEST hybrid PET/MRI

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2019-05-21
Est. Completion 2020-12-02
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT03923049

The ClinicalTrials.gov registry entry for NCT03923049 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which hybrid PET/MRI is the first listed.

NCT03923049 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03923049 about?

NCT03923049 is a clinical study titled "Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis". The purpose and objectives of the study is to establish the feasibility of the simultaneous PET/MR in patients with cardiac sarcoidosis, determine relationships between various imaging biomarkers like extracellular volume (ECV) and standardized uptake values (SUV) from FDG-PET and to evaluate the di...

What is the current status of trial NCT03923049?

This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2019-05-21. Estimated completion is 2020-12-02.

What interventions are being tested in trial NCT03923049?

The interventions under investigation include: hybrid PET/MRI (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03923049?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.